Epperly Melissa B,
- SEC CIK
- 0001807359
Latest role at each company
- ROIV Roivant Sciences Ltd.Directoras of Sep 18, 2026
- NAUT Nautilus Biotechnology, Inc.Directoras of Jun 22, 2026
- CIK 0001797768Directoras of Apr 5, 2024
- ZNTL Zentalis Pharmaceuticals, Inc.Chief Financial Officeras of Feb 12, 2024
Trades
Every Form 4 that lists Epperly Melissa B, as a reporting owner, including filings made jointly with others. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Company | Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| ROIVRoivant Sciences Ltd. | Sep 17, 20266:43 PM ET | Sep 15, 2026 | Epperly Melissa B,Director | SSaleCommon Shares | −4.94K | $39.7387 | −$196.23K | 9.9K | −33.3% | SEC10b5-1 |
| ROIVRoivant Sciences Ltd. | Jul 1, 20266:34 PM ET | Jun 29, 2026 | Epperly Melissa B,Director | SSaleCommon Shares | −17.75K | $34.3804 | −$610.25K | 16.47K | −51.9% | SEC10b5-1 |
| ROIVRoivant Sciences Ltd. | Mar 18, 2026 | Mar 16, 2026 | Epperly Melissa B,Director | SSaleCommon Shares | −41.86K | $28.68 | −$1.2M | 15.8K | −72.6% | SEC |
| ZNTLZentalis Pharmaceuticals, Inc. | Feb 12, 2024 | Feb 12, 2024 | Epperly Melissa B,Chief Financial Officer | SSaleCommon Stock | −2.57K | $11.44 | −$29.44K | 451.45K | −0.6% | SEC |
| ZNTLZentalis Pharmaceuticals, Inc. | Feb 5, 2024 | Feb 2, 2024 | Epperly Melissa B,Chief Financial Officer | SSaleCommon Stock | −8.67K | $11.54 | −$100.04K | 454.02K | −1.9% | SEC |
| ZNTLZentalis Pharmaceuticals, Inc. | Oct 6, 2023 | Oct 4, 2023 | Epperly Melissa B,Chief Financial Officer | SSaleCommon Stock | −5.48K | $19.5078 | −$106.94K | 387.69K | −1.4% | SEC10b5-1 |
| ZNTLZentalis Pharmaceuticals, Inc. | Feb 14, 2023 | Feb 13 – Feb 14, 2023 | Epperly Melissa B,Chief Financial Officer | SSaleCommon Stock | −7.85K | $20.1271 | −$158.02K | 392.05K | −2.0% | SEC |
| ZNTLZentalis Pharmaceuticals, Inc. | Apr 5, 2022 | Apr 4, 2022 | Epperly Melissa B,Chief Financial Officer | SSaleCommon Stock | −17.08K | $50.0916 | −$855.57K | 247.41K | −6.5% | SEC |
| ZNTLZentalis Pharmaceuticals, Inc. | Feb 23, 2022 | Feb 23, 2022 | Epperly Melissa B,Chief Financial Officer | SSaleCommon Stock | −1.91K | $49.0962 | −$93.92K | 264.49K | −0.7% | SEC |
| ZNTLZentalis Pharmaceuticals, Inc. | Aug 20, 2021 | Aug 18 – Aug 19, 2021 | Epperly Melissa B,Chief Financial Officer | PPurchaseCommon Stock | +9.61K | $52.00 | +$499.77K | 266.69K | +3.7% | SEC |
| ZNTLZentalis Pharmaceuticals, Inc. | Jul 6, 2021 | Jul 1, 2021 | Epperly Melissa B,Chief Financial Officer | SSaleCommon Stock | −3.08K | $51.2685 | −$158.06K | 257.07K | −1.2% | SEC |